Basic Company Data Data as of: March 28, 2011 Current Price $20.

25
Symbol PFE PFIZER INC H&C Composite Score
Description Pfizer Inc. is a research-based, global pharmaceutical company that discovers,
Strong Buy
develops, manufactures, and markets medicines for humans and animals. The
Company's products include prescription pharmaceuticals, non-prescription
self-medications, and animal health products such as anti-infective medicines
6.3
and vaccines.

Sector Health Care

Industry Pharmaceuticals, Biotechnology 0 1 2 3 4 5
Last Report Date 2/1/2011 Technical Score Fundamental Score
Earnings Date 5/4/2011 IPO Date #N/A N/A
Fundamentals Technicals
Market Cap. $161.9 B BETA 0.63 Price $20.25 MACD Trend Up
Price/Earnings 8.92 1Yr. EPS Growth Rate % 10.34% 50-Day MA $19.15 Stochastics Trend Down
Forward Price/Earnings 8.86 5Yr. Avg. EPS Growth Rate % 1.07% 200-Day MA $17.15 RSI Signal Trend Up
Price/Book 1.85 EPS Growth QoQ -4.08% 50/200 Day MA $1.99 S/T Trend Up
Forward PEG Ratio 3.38 Revenue Growth QoQ 6.19% Volume Pressure 1.24 L/T Trend Up
Return on Equity 25.04 Dividend Yield 3.95% Average Daily Volume 51,312,612 Bull / Bear Bull Trend
LT Debt/Equity 43.77% Cash Flow Per Share 1.43 M-Score (0 - 100%) 54%
H&C Fundamental Score 2.5 H&C Technical Score 3.8
Ownership Data
Inst. Buy/Sell Ratio 2.02 Management Ownership 0.08% 50 Day Moving Average S/T Support L/T Support
% Change of Insider Holdings 0.63% Short Interest Ratio 1.06 20 Day Moving Average S/T Resistance L/T Resistance

PFIZER INC $21

$20

$19

$18

$17

$16

4.0
Bull Trend Bear Trend
2.0

0.0

-2.0
2.0
Up / Down Volume Ratio
1.5
1.0
0.5
0.0
2,000

1,000

0
1-Dec-10 15-Dec-10 30-Dec-10 13-Jan-11 28-Jan-11 11-Feb-11 28-Feb-11 14-Mar-11 28-Mar-11
Volume x100,000
Fundamentals
PFIZER INC
1
Earnings Per Share 2
Reported Estimate Target Price 19 Reported Estimate
$0.80 $30

$0.60
$25

$0.40
$20
$0.20
$15
$0.00
$10
-$0.20

-$0.40 $5

-$0.60 $0

Total Revenues 1
Reported Estimate
Ownership EPS & Revenue Growth
Investment Advisor 85.41% Quarter EPS Growth Rev. Growth
$20,000
Hedge Fund Manager 5.57% FQ1 2009 -15% -8%
$18,000 Pension Fund (ERISA) 4.02% FQ2 2009 -13% -9%
Insurance Company 2.40% FQ3 2009 -16% -3%
$16,000
Mutual Fund Manager 1.40% FQ4 2009 -25% 34%
$14,000 Bank 0.51% FQ1 2010 23% 54%
$12,000
Corporation 0.21% FQ2 2010 29% 58%
Unclassified 0.19% FQ3 2010 4% 39%
$10,000 FQ4 2010 -4% 6%
$8,000 Top Holders and % Outstanding Forward Growth Estimates
$6,000 STATE STREET CORP 3.71% Quarter EPS Growth Rev. Growth
VANGUARD GROUP INC 3.62% FQ1 2011 -10% 0%
$4,000
WELLINGTON MANAGEMEN 3.15% FQ2 2011 -6% -1%
$2,000 BLACKROCK INSTITUTIO 2.52% FQ3 2011 3% 1%
BANK OF NEW YORK MEL 1.63% FQ4 2011 9% -4%
$0
ALLIANCEBERNSTEIN LP 1.61%
T ROWE PRICE ASSOCIA 1.48%
DODGE & COX 1.32%

Largest Geographic Segmentation of Revenue Product Segmentation of Revenue

Yearly Yearly
Segment Name FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 Segment Name FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
International 38,763.00 28,260.00 27,895.00 25,265.00 22,549.00 Biopharmaceutical $58,523.00 $45,448.00 $44,495.00 $44,424.00 $45,083.00
United States 29,046.00 21,749.00 20,401.00 23,153.00 25,822.00 Animal Health $3,575.00 $2,764.00 $2,825.00 $2,639.00 $2,311.00
Consumer Healthcare $2,772.00 $494.00 #N/A N/A #N/A N/A #N/A N/A
Nutrition $1,867.00 $191.00 #N/A N/A #N/A N/A #N/A N/A
Capsugel $752.00 $740.00 $767.00 #N/A N/A #N/A N/A
Corporate/Other $320.00 $372.00 $530.00 $1,355.00 $977.00

Disclosure: This material is provided for information only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. This material is not a complete analysis of all material facts respecting any issuer, industry or
security or of your investment objectives, parameters, needs or financial situation, and therefore is not a sufficient basis alone on which to base an investment decision. Horowitz & Company clients may hold positions (long or short) in investments discussed. Please click for detailed
disclosures and additional information about our stock ratings and scoring.

3/28/2011